

Magnetic resonance elastography predicts advanced fibrosis in nonalcoholic fatty liver disease: A prospective study

Hepatology

60, 1920-1928

DOI: [10.1002/hep.27362](https://doi.org/10.1002/hep.27362)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Non invasive tools for the diagnosis of liver cirrhosis. World Journal of Gastroenterology, 2014, 20, 18131.	1.4	76
2	Comparative diagnostic accuracy of magnetic resonance elastography vs. eight clinical prediction rules for non-invasive diagnosis of advanced fibrosis in biopsy-proven non-alcoholic fatty liver disease: a prospective study. Alimentary Pharmacology and Therapeutics, 2015, 41, 1271-1280.	1.9	125
3	Nonalcoholic fatty liver disease. Nature Reviews Disease Primers, 2015, 1, 15080.	18.1	612
4	Novel association between serum pentraxin-2 levels and advanced fibrosis in well-characterised patients with non-alcoholic fatty liver disease. Alimentary Pharmacology and Therapeutics, 2015, 42, 582-590.	1.9	19
5	Diagnostic usefulness of FibroMeter VCTE for hepatic fibrosis in patients with nonalcoholic fatty liver disease. European Journal of Gastroenterology and Hepatology, 2015, 27, 1149-1153.	0.8	21
6	Non-invasive diagnosis of liver fibrosis and cirrhosis. World Journal of Gastroenterology, 2015, 21, 11567.	1.4	237
7	Prediction of liver cirrhosis, using diagnostic imaging tools. World Journal of Hepatology, 2015, 7, 2069.	0.8	100
8	Personalized management of cirrhosis by non-invasive tests of liver fibrosis. Clinical and Molecular Hepatology, 2015, 21, 200.	4.5	29
9	Editorial: call to screen for <scp>NAFLD</scp> and <scp>NASH</scp> in psoriasis. Alimentary Pharmacology and Therapeutics, 2015, 41, 492-493.	1.9	1
10	Non-invasive diagnostic approach to non-alcoholic fatty liver disease: current evidence and future perspectives. Expert Review of Gastroenterology and Hepatology, 2015, 9, 1039-1053.	1.4	13
11	Nonalcoholic Fatty Liver Disease. JAMA - Journal of the American Medical Association, 2015, 313, 2263.	3.8	1,810
12	An Update of Liver Transplantation for Nonalcoholic Steatohepatitis. Current Hepatology Reports, 2015, 14, 99-108.	0.4	0
13	Noninvasive Testing for NASH and NASH with Advanced Fibrosis: Are We There Yet?. Current Hepatology Reports, 2015, 14, 109-118.	0.4	19
15	Polyunsaturated fatty acid metabolites as novel lipidomic biomarkers for noninvasive diagnosis of nonalcoholic steatohepatitis. Journal of Lipid Research, 2015, 56, 185-192.	2.0	160
16	Association Between Quantity of Liver Fat and Cardiovascular Risk in Patients With Nonalcoholic Fatty Liver Disease Independent of Nonalcoholic Steatohepatitis. Clinical Gastroenterology and Hepatology, 2015, 13, 1513-1520.e1.	2.4	85
17	Ezetimibe for the treatment of nonalcoholic steatohepatitis: Assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial). Hepatology, 2015, 61, 1239-1250.	3.6	296
18	Biochemical markers, liver biopsy, or magnetic resonance elastography to detect or exclude advanced fibrosis in patients with nonalcoholic fatty liver disease. Hepatology, 2015, 62, 324-325.	3.6	1
19	Accurate quantification of hepatic fat—is it important?. Nature Reviews Gastroenterology and Hepatology, 2015, 12, 126-127.	8.2	8

#	ARTICLE	IF	CITATIONS
20	Quantification of fibrosis by collagen proportionate area predicts hepatic decompensation in hepatitis C cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 477-486.	1.9	20
21	Recommendations for Diagnosis, Referral for Liver Biopsy, and Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. <i>Mayo Clinic Proceedings</i> , 2015, 90, 1233-1246.	1.4	214
22	Incorporation of Noninvasive Measures of Liver Fibrosis Into Clinical Practice: Diagnosis and Prognosis. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 2190-2204.	2.4	47
23	Clinical Model for NASH and Advanced Fibrosis in Adult Patients With Diabetes and NAFLD: Guidelines for Referral in NAFLD. <i>Diabetes Care</i> , 2015, 38, 1347-1355.	4.3	162
24	Magnetic resonance elastography of abdomen. <i>Abdominal Imaging</i> , 2015, 40, 745-759.	2.0	76
25	Two are better than one: noninvasive assessment of liver fibrosis in nonalcoholic fatty liver disease. <i>Hepatology International</i> , 2015, 9, 481-483.	1.9	2
26	Noninvasive Evaluation of Nonalcoholic Fatty Liver Disease. <i>Seminars in Liver Disease</i> , 2015, 35, 291-303.	1.8	65
27	Editorial: NAFLD in HIV infection - call for action. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 591-591.	1.9	2
28	Editorial: hepatocellular carcinoma "a rare complication of hepatic venous outflow tract obstruction" authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 1213-1214.	1.9	0
29	Editorial: hepatocellular carcinoma "a rare complication of hepatic venous outflow tract obstruction. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 1212-1213.	1.9	2
30	Shear Wave Elastography for Assessment of Steatohepatitis and Hepatic Fibrosis in Rat Models of Non-Alcoholic Fatty Liver Disease. <i>Ultrasound in Medicine and Biology</i> , 2015, 41, 3205-3215.	0.7	21
31	Caring for children with NAFLD and navigating their care into adulthood. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2015, 12, 617-628.	8.2	17
32	3D molecular MR imaging of liver fibrosis and response to rapamycin therapy in a bile duct ligation rat model. <i>Journal of Hepatology</i> , 2015, 63, 689-696.	1.8	57
33	Heritability of Hepatic Fibrosis and Steatosis Based on a Prospective Twin Study. <i>Gastroenterology</i> , 2015, 149, 1784-1793.	0.6	294
34	Diagnostic Performance of Magnetic Resonance Elastography in Staging Liver Fibrosis: A Systematic Review and Meta-analysis of Individual Participant Data. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 440-451.e6.	2.4	427
35	General review of magnetic resonance elastography. <i>World Journal of Radiology</i> , 2016, 8, 59.	0.5	82
36	Magnetic Resonance Elastography and Other Magnetic Resonance Imaging Techniques in Chronic Liver Disease: Current Status and Future Directions. <i>Gut and Liver</i> , 2016, 10, 672-686.	1.4	35
37	Non-Alcoholic Steatohepatitis: Clinical and Translational Research. <i>Journal of Pharmacy and Pharmaceutical Sciences</i> , 2016, 19, 8.	0.9	4

#	ARTICLE	IF	CITATIONS
38	Non-invasive Markers of Liver Fibrosis: Adjuncts or Alternatives to Liver Biopsy?. <i>Frontiers in Pharmacology</i> , 2016, 7, 159.	1.6	67
39	Noninvasive Markers to Assess Liver Fibrosis. <i>Journal of Clinical Gastroenterology</i> , 2016, 50, 445-457.	1.1	14
40	Performance of noninvasive models of fibrosis in predicting mild to moderate fibrosis in patients with nonalcoholic fatty liver disease. <i>Liver International</i> , 2016, 36, 572-579.	1.9	38
41	Magnetic resonance elastography: Better, but still the same!. <i>Hepatology</i> , 2016, 64, 2262-2263.	3.6	0
42	Evaluation of liver stiffness with magnetic resonance elastography in patients with constrictive pericarditis: Preliminary findings. <i>Journal of Magnetic Resonance Imaging</i> , 2016, 44, 81-88.	1.9	10
43	Liver transplantation for nonalcoholic steatohepatitis in young patients. <i>Transplant International</i> , 2016, 29, 418-424.	0.8	68
44	Reply. <i>Hepatology</i> , 2016, 64, 2263-2263.	3.6	0
45	Shared genetic effects between hepatic steatosis and fibrosis: A prospective twin study. <i>Hepatology</i> , 2016, 64, 1547-1558.	3.6	64
46	Noninvasive imaging methods to determine severity of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. <i>Hepatology</i> , 2016, 64, 2234-2243.	3.6	54
47	Prospective comparison of magnetic resonance imaging to transient elastography and serum markers for liver fibrosis detection. <i>Liver International</i> , 2016, 36, 659-666.	1.9	54
48	Magnetic resonance elastography (MRE) of the human brain: technique, findings and clinical applications. <i>Physics in Medicine and Biology</i> , 2016, 61, R401-R437.	1.6	176
49	Sitagliptin vs. placebo for non-alcoholic fatty liver disease: A randomized controlled trial. <i>Journal of Hepatology</i> , 2016, 65, 369-376.	1.8	264
50	Nonalcoholic Fatty Liver Disease: Pathogenesis and Disease Spectrum. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2016, 11, 451-496.	9.6	449
51	Nonalcoholic Fatty Liver Disease and Liver Transplantation. <i>Clinics in Liver Disease</i> , 2016, 20, 403-417.	1.0	12
52	Time Harmonic Elastography Reveals Sensitivity of Liver Stiffness to Water Ingestion. <i>Ultrasound in Medicine and Biology</i> , 2016, 42, 1289-1294.	0.7	31
53	Promising therapies for treatment of nonalcoholic steatohepatitis. <i>Expert Opinion on Emerging Drugs</i> , 2016, 21, 343-357.	1.0	28
54	Noninvasive screening of diabetics in primary care for NAFLD and advanced fibrosis by MRI and MRE. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 83-95.	1.9	168
55	Magnetic resonance elastography identifies fibrosis in adults with alpha ₁ -antitrypsin deficiency liver disease: a prospective study. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 44, 287-299.	1.9	31

#	ARTICLE	IF	CITATIONS
56	Biomarkers of liver fibrosis. <i>Clinical Liver Disease</i> , 2016, 7, 139-142.	1.0	7
57	Targeting Hepatic Fibrosis in Autoimmune Hepatitis. <i>Digestive Diseases and Sciences</i> , 2016, 61, 3118-3139.	1.1	28
58	MRI and MRE for non-invasive quantitative assessment of hepatic steatosis and fibrosis in NAFLD and NASH: Clinical trials to clinical practice. <i>Journal of Hepatology</i> , 2016, 65, 1006-1016.	1.8	275
59	Feasibility of transient elastography versus real-time two-dimensional shear wave elastography in difficult-to-scan patients. <i>Scandinavian Journal of Gastroenterology</i> , 2016, 51, 1354-1359.	0.6	23
60	Liver resection for cancer: New developments in prediction, prevention and management of postresectional liver failure. <i>Journal of Hepatology</i> , 2016, 65, 1217-1231.	1.8	96
61	Editorial: A New Spin on Magnetic Resonance Elastography. <i>American Journal of Gastroenterology</i> , 2016, 111, 834-837.	0.2	1
62	Liver Stiffness Measurements with MR Elastography: Agreement and Repeatability across Imaging Systems, Field Strengths, and Pulse Sequences. <i>Radiology</i> , 2016, 281, 793-804.	3.6	105
63	Noninvasive evaluation of nonalcoholic fatty liver disease. <i>Clinical Liver Disease</i> , 2016, 7, 45-47.	1.0	3
64	Magnetic resonance elastography is superior to acoustic radiation force impulse for the Diagnosis of fibrosis in patients with biopsy-proven nonalcoholic fatty liver disease: A prospective study. <i>Hepatology</i> , 2016, 63, 453-461.	3.6	168
65	Comparison of multislice breath-hold and 3D respiratory triggered T_1 -imaging of liver in healthy volunteers and liver cirrhosis patients in 3.0 T MRI. <i>Journal of Magnetic Resonance Imaging</i> , 2016, 44, 906-913.	1.9	10
66	Biopsy and Noninvasive Methods to Assess Progression of Nonalcoholic Fatty Liver Disease. <i>Gastroenterology</i> , 2016, 150, 1811-1822.e4.	0.6	93
67	Magnetic Resonance Elastography for the Evaluation of Liver Fibrosis in Chronic Hepatitis B and C by Using Both Gradient-Recalled Echo and Spin-Echo Echo Planar Imaging: A Prospective Study. <i>American Journal of Gastroenterology</i> , 2016, 111, 823-833.	0.2	66
68	Staging of fibrosis in experimental non-alcoholic steatohepatitis by quantitative molecular imaging in rat models. <i>Nuclear Medicine and Biology</i> , 2016, 43, 179-187.	0.3	9
69	Novel 3D Magnetic Resonance Elastography for the Noninvasive Diagnosis of Advanced Fibrosis in NAFLD: A Prospective Study. <i>American Journal of Gastroenterology</i> , 2016, 111, 986-994.	0.2	160
70	Systematic review with meta-analysis: diagnostic accuracy of transient elastography for staging of fibrosis in people with alcoholic liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 575-585.	1.9	57
71	Clinical Presentation and Patient Evaluation in Nonalcoholic Fatty Liver Disease. <i>Clinics in Liver Disease</i> , 2016, 20, 277-292.	1.0	32
72	Epidemiology and natural history of non-alcoholic fatty liver disease. <i>Metabolism: Clinical and Experimental</i> , 2016, 65, 1017-1025.	1.5	339
73	Magnetic Resonance Imaging/Elastography Is Superior to Transient Elastography for Detection of Liver Fibrosis and Fat in Nonalcoholic Fatty Liver Disease. <i>Gastroenterology</i> , 2016, 150, 553-556.	0.6	12

#	ARTICLE	IF	CITATIONS
74	Noninvasive diagnosis of nonalcoholic fatty liver disease: Are we there yet?. <i>Metabolism: Clinical and Experimental</i> , 2016, 65, 1087-1095.	1.5	53
75	Management of NAFLD: a stage-based approach. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2016, 13, 196-205.	8.2	287
76	Doppler ultrasonography helps discriminate between cirrhotic and non-cirrhotic patients with viral B and C hepatitis. <i>Diagnostic and Interventional Imaging</i> , 2016, 97, 339-345.	1.8	6
77	Magnetic Resonance Imaging More Accurately Classifies Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease Than Transient Elastography. <i>Gastroenterology</i> , 2016, 150, 626-637.e7.	0.6	628
78	Current complications and challenges in nonalcoholic steatohepatitis screening and diagnosis. <i>Expert Review of Gastroenterology and Hepatology</i> , 2016, 10, 63-71.	1.4	50
79	Magnetic resonance elastography for staging liver fibrosis in non-alcoholic fatty liver disease: a diagnostic accuracy systematic review and individual participant data pooled analysis. <i>European Radiology</i> , 2016, 26, 1431-1440.	2.3	195
80	Letter: comparative diagnostic accuracy of magnetic resonance elastography vs. eight clinical prediction rules for noninvasive diagnosis of advanced fibrosis in biopsy-proven NAFLD. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 478-479.	1.9	2
81	Letter: comparative diagnostic accuracy of magnetic resonance elastography vs. eight clinical prediction rules for noninvasive diagnosis of advanced fibrosis in biopsy-proven NAFLD – author's reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 479-479.	1.9	0
82	Distinguishing between Hepatic Inflammation and Fibrosis with MR Elastography. <i>Radiology</i> , 2017, 284, 694-705.	3.6	117
83	Liver fibrogenesis. , 2017, , 110-122.e5.		0
84	Magnetic resonance imaging and transient elastography in the management of Nonalcoholic Fatty Liver Disease (NAFLD). <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 379-390.	1.3	30
85	Assessment of treatment response in nonalcoholic steatohepatitis using advanced magnetic resonance imaging. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 844-854.	1.9	21
86	Predicting postoperative outcomes of liver resection by magnetic resonance elastography. <i>Surgery</i> , 2017, 162, 248-255.	1.0	21
87	Magnetic resonance elastography measured shear stiffness as a biomarker of fibrosis in pediatric nonalcoholic fatty liver disease. <i>Hepatology</i> , 2017, 66, 1474-1485.	3.6	103
88	Randomized Controlled Trial of a MUFA or Fiber-Rich Diet on Hepatic Fat in Prediabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 1765-1774.	1.8	61
89	Editorial: Age and Non-Invasive Markers of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease: Time to Adjust the Clock?. <i>American Journal of Gastroenterology</i> , 2017, 112, 752-754.	0.2	6
90	The Almost-Normal Liver Biopsy. <i>American Journal of Surgical Pathology</i> , 2017, 41, 1247-1253.	2.1	18
91	Repeatability and reproducibility of 2D and 3D hepatic MR elastography with rigid and flexible drivers at end-expiration and end-inspiration in healthy volunteers. <i>Abdominal Radiology</i> , 2017, 42, 2843-2854.	1.0	34

#	ARTICLE	IF	CITATIONS
92	Noninvasive diagnosis of liver fibrosis in adults. <i>Clinical Liver Disease</i> , 2017, 9, 121-124.	1.0	5
93	MR elastography: high rate of technical success in pediatric and young adult patients. <i>Pediatric Radiology</i> , 2017, 47, 838-843.	1.1	44
94	Comparison of spin-echo echoplanar imaging and gradient recalled echo-based MR elastography at 3 Tesla with and without gadoxetic acid administration. <i>European Radiology</i> , 2017, 27, 4120-4128.	2.3	18
95	Force-dependent breaching of the basement membrane. <i>Matrix Biology</i> , 2017, 57-58, 178-189.	1.5	66
96	Multiparametric or practical quantitative liver MRI: towards millisecond, fat fraction, kilopascal and function era. <i>Expert Review of Gastroenterology and Hepatology</i> , 2017, 11, 167-182.	1.4	27
97	Diagnosing liver fibrosis: a narrative review of current literature for dermatologists. <i>British Journal of Dermatology</i> , 2017, 177, 637-644.	1.4	8
98	Application of the combined FibroMeter vibration-controlled transient elastography algorithm in Chinese patients with nonalcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 1363-1369.	1.4	44
99	Use of Liver Imaging and Biopsy in Clinical Practice. <i>New England Journal of Medicine</i> , 2017, 377, 756-768.	13.9	280
100	Evaluation of Non-alcoholic Fatty Liver Disease Using Acoustic Radiation Force Impulse Imaging Elastography in Rat Models. <i>Ultrasound in Medicine and Biology</i> , 2017, 43, 2619-2628.	0.7	8
101	Liver Fibrosis Quantification by Magnetic Resonance Imaging. <i>Topics in Magnetic Resonance Imaging</i> , 2017, 26, 229-241.	0.7	43
102	The role of bariatric surgery in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. <i>Expert Review of Gastroenterology and Hepatology</i> , 2017, 11, 797-811.	1.4	24
103	Fibrosis imaging: Current concepts and future directions. <i>Advanced Drug Delivery Reviews</i> , 2017, 121, 9-26.	6.6	110
104	Multiorgan, Multimodality Imaging in Cardiometabolic Disease. <i>Circulation: Cardiovascular Imaging</i> , 2017, 10, .	1.3	8
105	Combined magnetic resonance elastography and collagen molecular magnetic resonance imaging accurately stage liver fibrosis in a rat model. <i>Hepatology</i> , 2017, 65, 1015-1025.	3.6	43
106	Multiparametric magnetic resonance imaging for the assessment of nonalcoholic fatty liver disease severity. <i>Liver International</i> , 2017, 37, 1065-1073.	1.9	145
107	Magnetic Resonance Elastography vs Transient Elastography in Detection of Fibrosis and Noninvasive Measurement of Steatosis in Patients With Biopsy-Proven Nonalcoholic Fatty Liver Disease. <i>Gastroenterology</i> , 2017, 152, 598-607.e2.	0.6	510
108	Detection of Steatohepatitis in a Rat Model by Using Spectroscopic Shear-Wave US Elastography. <i>Radiology</i> , 2017, 282, 726-733.	3.6	13
109	Hepatic stiffness measurement by using MR elastography: prognostic values after hepatic resection for hepatocellular carcinoma. <i>European Radiology</i> , 2017, 27, 1713-1721.	2.3	41

#	ARTICLE	IF	CITATIONS
110	Assessment of Nonalcoholic Fatty Liver Disease in Rats Using Quantitative Dynamic Contrast-Enhanced MRI. <i>Journal of Magnetic Resonance Imaging</i> , 2017, 45, 1485-1493.	1.9	7
111	Weight Loss Decreases Magnetic Resonance Elastography Estimated Liver Stiffness in Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 463-464.	2.4	29
112	Identifying nonalcoholic fatty liver disease patients with active fibrosis by measuring extracellular matrix remodeling rates in tissue and blood. <i>Hepatology</i> , 2017, 65, 78-88.	3.6	83
113	Nonalcoholic fatty liver disease: one entity, multiple impacts on liver health. <i>Cell Biology and Toxicology</i> , 2017, 33, 5-14.	2.4	11
114	Improved noninvasive prediction of liver fibrosis by liver stiffness measurement in patients with nonalcoholic fatty liver disease accounting for controlled attenuation parameter values. <i>Hepatology</i> , 2017, 65, 1145-1155.	3.6	177
115	Imaging-Based Assessment of Steatosis, Inflammation and Fibrosis in NAFLD. <i>Current Hepatology Reports</i> , 2017, 16, 298-307.	0.4	9
116	A prediction model for the grade of liver fibrosis using magnetic resonance elastography. <i>BMC Gastroenterology</i> , 2017, 17, 133.	0.8	6
117	Nonalcoholic fatty liver disease with cirrhosis increases familial risk for advanced fibrosis. <i>Journal of Clinical Investigation</i> , 2017, 127, 2697-2704.	3.9	137
118	Noninvasive diagnosis of nonalcoholic fatty liver disease, is the more expensive the better?. <i>AME Medical Journal</i> , 0, 2, 171-171.	0.4	1
119	Magnetic Resonance Elastography Shear Wave Velocity Correlates with Liver Fibrosis and Hepatic Venous Pressure Gradient in Adults with Advanced Liver Disease. <i>BioMed Research International</i> , 2017, 2017, 1-8.	0.9	29
120	Magnetic resonance elastography is accurate in detecting advanced fibrosis in autoimmune hepatitis. <i>World Journal of Gastroenterology</i> , 2017, 23, 859.	1.4	51
121	Noninvasive imaging biomarker assessment of liver fibrosis by elastography in NAFLD. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2018, 15, 274-282.	8.2	124
122	Quantitative Elastography Methods in Liver Disease: Current Evidence and Future Directions. <i>Radiology</i> , 2018, 286, 738-763.	3.6	215
123	Can Elastography Differentiate Isolated Fatty Liver from Nonalcoholic Steatohepatitis?. <i>Seminars in Liver Disease</i> , 2018, 38, 014-020.	1.8	21
124	Diagnostic Performance of MR Elastography for Liver Fibrosis in Children and Young Adults with a Spectrum of Liver Diseases. <i>Radiology</i> , 2018, 287, 824-832.	3.6	73
125	When and How to Use Magnetic Resonance Elastography for Patients With Liver Disease in Clinical Practice. <i>American Journal of Gastroenterology</i> , 2018, 113, 923-926.	0.2	16
126	Prognostic Role of Liver Stiffness Measurements Using Magnetic Resonance Elastography in Patients with Compensated Chronic Liver Disease. <i>European Radiology</i> , 2018, 28, 3513-3521.	2.3	24
127	Liver Stiffness Measured by Two-Dimensional Shear-Wave Elastography: Prognostic Value after Radiofrequency Ablation for Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2018, 7, 65-75.	4.2	23

#	ARTICLE	IF	CITATIONS
128	Abbreviated mpMRI protocol for diffuse liver disease: a practical approach for evaluation and follow-up of NAFLD. <i>Abdominal Radiology</i> , 2018, 43, 2340-2350.	1.0	23
129	Magnetic resonance elastography of liver and spleen: Methods and applications. <i>NMR in Biomedicine</i> , 2018, 31, e3891.	1.6	30
130	Association Between Obesity and Discordance in Fibrosis Stage Determination by Magnetic Resonance vs Transient Elastography in Patients With Nonalcoholic Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1974-1982.e7.	2.4	46
131	Viral eradication reduces both liver stiffness and steatosis in patients with chronic hepatitis C virus infection who received direct-acting antiviral therapy. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1012-1022.	1.9	50
132	Origins of Portal Hypertension in Nonalcoholic Fatty Liver Disease. <i>Digestive Diseases and Sciences</i> , 2018, 63, 563-576.	1.1	39
133	MR elastography is effective for the non-invasive evaluation of fibrosis and necroinflammatory activity in patients with nonalcoholic fatty liver disease. <i>European Journal of Radiology</i> , 2018, 98, 82-89.	1.2	46
134	Feasibility and agreement of stiffness measurements using gradient-echo and spin-echo MR elastography sequences in unselected patients undergoing liver MRI. <i>British Journal of Radiology</i> , 2018, 91, 20180126.	1.0	12
135	Non-invasive markers of liver fibrosis in fatty liver disease are unreliable in people of South Asian descent. <i>Frontline Gastroenterology</i> , 2018, 9, 115-121.	0.9	23
136	Prevalent Cardiovascular Disease Events and T1 Mapping Defined Hepatic Fibrosis. <i>Circulation: Cardiovascular Imaging</i> , 2018, 11, e007553.	1.3	5
138	Diseases of the Abdomen and Pelvis 2018-2021. <i>IDKD Springer Series</i> , 2018, , .	0.8	22
139	Assessment of biopsy-proven liver fibrosis by two-dimensional shear wave elastography: An individual patient data-based meta-analysis. <i>Hepatology</i> , 2018, 67, 260-272.	3.6	322
140	Stable isotope-based flux studies in nonalcoholic fatty liver disease. , 2018, 181, 22-33.		14
141	The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. <i>Hepatology</i> , 2018, 67, 328-357.	3.6	4,738
142	Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science. <i>Hepatology</i> , 2018, 67, 2001-2012.	3.6	125
143	Increased severity of liver fat content and liver fibrosis in non-alcoholic fatty liver disease correlate with epicardial fat volume in type 2 diabetes: A prospective study. <i>European Radiology</i> , 2018, 28, 1345-1355.	2.3	31
144	Quantitative magnetic resonance imaging phantoms: A review and the need for a system phantom. <i>Magnetic Resonance in Medicine</i> , 2018, 79, 48-61.	1.9	116
145	Magnetic resonance elastography is as accurate as liver biopsy for liver fibrosis staging. <i>Journal of Magnetic Resonance Imaging</i> , 2018, 47, 1268-1275.	1.9	51
146	Non-invasive Evaluation of NAFLD with Indocyanine Green Clearance Test: a Preliminary Study in Morbidly Obese Patients Undergoing Bariatric Surgery. <i>Obesity Surgery</i> , 2018, 28, 735-742.	1.1	11

#	ARTICLE	IF	CITATIONS
147	Quantitative MRI of fatty liver disease in a large pediatric cohort: correlation between liver fat fraction, stiffness, volume, and patient-specific factors. <i>Abdominal Radiology</i> , 2018, 43, 1168-1179.	1.0	31
148	Comparison of gradient-recalled echo and spin-echo echo-planar imaging MR elastography in staging liver fibrosis: a meta-analysis. <i>European Radiology</i> , 2018, 28, 1709-1718.	2.3	49
149	Clinical strategy of diagnosing and following patients with nonalcoholic fatty liver disease based on invasive and noninvasive methods. <i>Journal of Gastroenterology</i> , 2018, 53, 181-196.	2.3	61
151	Clinical relevance of liver histopathology and different histological classifications of NASH in adults. <i>Expert Review of Gastroenterology and Hepatology</i> , 2018, 12, 351-367.	1.4	47
152	Detection of liver fibrosis using qualitative and quantitative MR elastography compared to liver surface nodularity measurement, gadoteric acid uptake, and serum markers. <i>Journal of Magnetic Resonance Imaging</i> , 2018, 47, 1552-1561.	1.9	36
153	Systematic review and meta-analysis: noninvasive detection of nonalcoholic fatty liver disease related fibrosis in the obese. <i>Obesity Reviews</i> , 2018, 19, 281-294.	3.1	22
154	Role of two-dimensional shear wave elastography in the assessment of chronic liver diseases. <i>Hepatology</i> , 2018, 67, 13-15.	3.6	9
155	Assessment of advanced hepatic MR elastography methods for susceptibility artifact suppression in clinical patients. <i>Journal of Magnetic Resonance Imaging</i> , 2018, 47, 976-987.	1.9	28
156	NON-ALCOHOLIC FATTY LIVER DISEASE: AN UPDATE ON DIAGNOSIS. <i>Medicine and Pharmacy Reports</i> , 2018, 91, 147-150.	0.2	33
157	Progress in non-invasive detection of liver fibrosis. <i>Cancer Biology and Medicine</i> , 2018, 15, 124.	1.4	71
158	Recommendations for the management of non-alcoholic fatty liver disease (NAFLD). <i>Clinical and Experimental Hepatology</i> , 2018, 4, 153-157.	0.6	15
159	Magnetic Resonance Elastography of Liver. <i>Topics in Magnetic Resonance Imaging</i> , 2018, 27, 319-333.	0.7	92
160	Non-alcoholic fatty liver disease: controlling an emerging epidemic, challenges, and future directions. <i>Annals of Gastroenterology</i> , 2018, 31, 288-295.	0.4	54
161	Nonalcoholic fatty liver disease: current concepts, epidemiology and management strategies. <i>European Journal of Gastroenterology and Hepatology</i> , 2018, 30, 1103-1115.	0.8	56
162	Imaging of Hepatic Fibrosis. <i>Current Gastroenterology Reports</i> , 2018, 20, 45.	1.1	29
163	Stiffness reconstruction methods for MR elastography. <i>NMR in Biomedicine</i> , 2018, 31, e3935.	1.6	59
164	Diagnostic performance of magnetic resonance technology in detecting steatosis or fibrosis in patients with nonalcoholic fatty liver disease. <i>Medicine (United States)</i> , 2018, 97, e10605.	0.4	14
165	Assessment of Nonalcoholic Fatty Liver Disease Progression in Children Using Magnetic Resonance Imaging. <i>Journal of Pediatrics</i> , 2018, 201, 86-92.	0.9	28

#	ARTICLE	IF	CITATIONS
166	The role of imaging in prediction of post-hepatectomy liver failure. <i>Clinical Imaging</i> , 2018, 52, 137-145.	0.8	17
167	Diagnostic Methods of Cirrhosis and Portal Hypertension: Specifics of the Pediatric Population. , 2018, , 325-341.		0
168	Accuracy of non-invasive scoring systems for diagnosing non-alcoholic steatohepatitis-related fibrosis: Multicenter validation study. <i>Hepatology Research</i> , 2018, 48, 1099-1107.	1.8	22
169	Clinical application of magnetic resonance elastography in chronic liver disease. <i>Hepatology Research</i> , 2018, 48, 780-787.	1.8	10
170	Tests for diagnosing and monitoring non-alcoholic fatty liver disease in adults. <i>BMJ: British Medical Journal</i> , 2018, 362, k2734.	2.4	81
171	Role of acoustic radiation force impulse imaging elastography in the assessment of steatohepatitis and fibrosis in rat models. <i>Medical Engineering and Physics</i> , 2018, 59, 30-35.	0.8	4
172	Proteomic identification and characterization of hepatic glyoxalase 1 dysregulation in non-alcoholic fatty liver disease. <i>Proteome Science</i> , 2018, 16, 4.	0.7	20
173	Growth velocity of the portal vein tumor thrombus accelerated by its progression, alpha-fetoprotein level, and liver fibrosis stage in patients with hepatocellular carcinoma. <i>Surgery</i> , 2018, 164, 1014-1022.	1.0	11
174	Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. <i>Journal of Hepatology</i> , 2018, 69, 896-904.	1.8	1,157
176	Magnetic Resonance vs Transient Elastography Analysis of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Pooled Analysis of Individual Participants. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 630-637.e8.	2.4	254
177	Evolving Management Strategies for Nonalcoholic Fatty Liver Disease-Targeting Primary Care Physicians. <i>Diabetes Technology and Therapeutics</i> , 2019, 21, 611-618.	2.4	1
179	Duodenal and Rectal Mucosa Inflammation in Patients With Nonceliac Wheat Sensitivity. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2140-2141.	2.4	0
180	CON: This Patient Should Have a Noninvasive Assessment of Liver Staging. <i>Clinical Liver Disease</i> , 2019, 14, 116-120.	1.0	0
181	Overview of emerging treatment of non-alcoholic fatty liver disease: more than one drug needed?. <i>Hepatobiliary Surgery and Nutrition</i> , 2019, 8, 522-524.	0.7	3
182	Performance of the PRO-C3 collagen neo-epitope biomarker in non-alcoholic fatty liver disease. <i>JHEP Reports</i> , 2019, 1, 188-198.	2.6	86
183	Imaging inflammation and its resolution in health and disease: current status, clinical needs, challenges, and opportunities. <i>FASEB Journal</i> , 2019, 33, 13085-13097.	0.2	13
184	Pilot Study to Diagnose Nonalcoholic Steatohepatitis With Dynamic ¹⁸ F-FDG PET. <i>American Journal of Roentgenology</i> , 2019, 212, 529-537.	1.0	19
185	Elastodiagnosis of diseases: A review. <i>Extreme Mechanics Letters</i> , 2019, 27, 102-123.	2.0	19

#	ARTICLE	IF	CITATIONS
186	Non-alcoholic fatty liver infiltration in children: an underdiagnosed evolving disease. <i>Hormones</i> , 2019, 18, 255-265.	0.9	6
187	Pro: Noninvasive Imaging Has Replaced Biopsy as the Gold Standard in the Evaluation of Nonalcoholic Fatty Liver Disease. <i>Clinical Liver Disease</i> , 2019, 13, 111-113.	1.0	11
188	Diagnosis and management of non-alcoholic fatty liver disease. <i>Postgraduate Medical Journal</i> , 2019, 95, 314-322.	0.9	70
189	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2140.	2.4	0
190	Albuminâ€“bilirubin score indicates liver fibrosis staging and prognosis in patients with chronic hepatitis C. <i>Hepatology Research</i> , 2019, 49, 731-742.	1.8	40
191	Pediatric NAFLD: an overview and recent developments in diagnostics and treatment. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019, 13, 447-461.	1.4	67
192	Current Management Strategy of Non-Alcoholic Fatty Liver Disease. <i>Journal of Enam Medical College</i> , 2019, 9, 46-56.	0.1	0
193	Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease. <i>Gastroenterology</i> , 2019, 156, 1264-1281.e4.	0.6	882
194	Collagen Formation Assessed by Nâ€“terminal Propeptide of Type 3 Procollagen Is a Heritable Trait and Is Associated With Liver Fibrosis Assessed by Magnetic Resonance Elastography. <i>Hepatology</i> , 2019, 70, 127-141.	3.6	21
195	Accuracy of imaging methods for steatohepatitis diagnosis in nonâ€“alcoholic fatty liver disease patients: A systematic review. <i>Liver International</i> , 2019, 39, 1521-1534.	1.9	24
196	A gut microbiome signature for cirrhosis due to nonalcoholic fatty liver disease. <i>Nature Communications</i> , 2019, 10, 1406.	5.8	218
197	Current Noninvasive MR-Based Imaging Methods in Assessing NAFLD Patients. , 0, , .		0
198	Tomoelastography for the Evaluation of Pediatric Nonalcoholic Fatty Liver Disease. <i>Investigative Radiology</i> , 2019, 54, 198-203.	3.5	28
199	A gathering storm. <i>Aids</i> , 2019, 33, 1105-1115.	1.0	18
200	Nonalcoholic Fatty Liver Disease: Identification and Management of High-Risk Patients. <i>American Journal of Gastroenterology</i> , 2019, 114, 579-590.	0.2	27
201	Serum metabolites detect the presence of advanced fibrosis in derivation and validation cohorts of patients with non-alcoholic fatty liver disease. <i>Gut</i> , 2019, 68, 1884-1892.	6.1	48
202	Systematic review: diagnostic accuracy of non-invasive tests for staging liver fibrosis in autoimmune hepatitis. <i>Hepatology International</i> , 2019, 13, 91-101.	1.9	43
203	Simultaneous acquisition of magnetic resonance elastography of the supraspinatus and the trapezius muscles. <i>Magnetic Resonance Imaging</i> , 2019, 57, 95-102.	1.0	10

#	ARTICLE	IF	CITATIONS
204	Magnetic resonance elastography SE-EPI vs GRE sequences at 3T in a pediatric population with liver disease. <i>Abdominal Radiology</i> , 2019, 44, 894-902.	1.0	22
205	Noninvasive diagnosis of nonalcoholic steatohepatitis: Emerging approaches. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2019, 18, 1-3.	0.6	2
206	Narrowband Shear Wave Generation Using Sinusoidally Modulated Acoustic Radiation Force. <i>IEEE Transactions on Ultrasonics, Ferroelectrics, and Frequency Control</i> , 2019, 66, 264-272.	1.7	9
207	Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: Analysis of data from a phase II trial of selonsertib. <i>Journal of Hepatology</i> , 2019, 70, 133-141.	1.8	149
208	Iodine density Changes in Hepatic and Splenic Parenchyma in Liver Cirrhosis with Dual Energy CT (DECT): A Preliminary Study. <i>Academic Radiology</i> , 2019, 26, 872-877.	1.3	13
209	The Role of Three-Dimensional Magnetic Resonance Elastography in the Diagnosis of Nonalcoholic Steatohepatitis in Obese Patients Undergoing Bariatric Surgery. <i>Hepatology</i> , 2020, 71, 510-521.	3.6	65
210	Liver stiffness does not affect ultrasound-guided attenuation coefficient measurement in the evaluation of hepatic steatosis. <i>Hepatology Research</i> , 2020, 50, 190-198.	1.8	35
211	How to Identify the Patient with Nonalcoholic Steatohepatitis Who Will Progress to Cirrhosis. <i>Gastroenterology Clinics of North America</i> , 2020, 49, 45-62.	1.0	5
212	The Role of Noninvasive Tests for Differentiating NASH From NAFL and Diagnosing Advanced Fibrosis Among Patients With NAFLD. <i>Journal of Clinical Gastroenterology</i> , 2020, 54, 107-113.	1.1	21
213	Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver Diseases. <i>Hepatology</i> , 2020, 72, 671-722.	3.6	473
214	Clinical Characteristics of a Non-Alcoholic Fatty Liver Disease Population Across the Fibrosis Spectrum Measured by Magnetic Resonance Elastography: Analysis of Screening Data. <i>Advances in Therapy</i> , 2020, 37, 4866-4876.	1.3	4
215	Liver Stiffness by Magnetic Resonance Elastography Predicts Future Cirrhosis, Decompensation, and Death in NAFLD. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1915-1924.e6.	2.4	57
217	NAFLD as a continuum: from obesity to metabolic syndrome and diabetes. <i>Diabetology and Metabolic Syndrome</i> , 2020, 12, 60.	1.2	321
218	Sound transmission in human thorax through airway insonification: an experimental and computational study with diagnostic applications. <i>Medical and Biological Engineering and Computing</i> , 2020, 58, 2239-2258.	1.6	8
219	MR elastography-based liver fibrosis correlates with liver events in nonalcoholic fatty liver patients: A multicenter study. <i>Liver International</i> , 2020, 40, 2242-2251.	1.9	48
220	Magnetic resonance-based biomarkers in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. <i>Endocrinology, Diabetes and Metabolism</i> , 2020, 3, e00134.	1.0	11
221	MRE combined with FIB-4 (MEFIB) index in detection of candidates for pharmacological treatment of NASH-related fibrosis. <i>Gut</i> , 2021, 70, 1946-1953.	6.1	78
222	Multiparametric MR mapping in clinical decision-making for diffuse liver disease. <i>Abdominal Radiology</i> , 2020, 45, 3507-3522.	1.0	30

#	ARTICLE	IF	CITATIONS
223	MR elastography of liver: current status and future perspectives. <i>Abdominal Radiology</i> , 2020, 45, 3444-3462.	1.0	56
224	Magnetic resonance imaging for the assessment of pathological hepatic findings in nonalcoholic fatty liver disease. <i>Journal of Medical Ultrasonics (2001)</i> , 2020, 47, 535-548.	0.6	9
225	Magnetic Resonance imaging analysis of liver fibrosis and inflammation: overwhelming gray zones restrict clinical use. <i>Abdominal Radiology</i> , 2020, 45, 3557-3568.	1.0	5
226	Noninvasive Tests (NITs) for Hepatic Fibrosis in Fatty Liver Syndrome. <i>Life</i> , 2020, 10, 198.	1.1	11
227	Screening and follow-up of chronic liver diseases with understanding their etiology in clinics and hospitals. <i>JGH Open</i> , 2020, 4, 827-837.	0.7	3
228	Advanced MRI of Liver Fibrosis and Treatment Response in a Rat Model of Nonalcoholic Steatohepatitis. <i>Radiology</i> , 2020, 296, 67-75.	3.6	22
230	Advances in Magnetic Resonance Elastography of Liver. <i>Magnetic Resonance Imaging Clinics of North America</i> , 2020, 28, 331-340.	0.6	19
231	Clinical assessment for high-risk patients with non-alcoholic fatty liver disease in primary care and diabetology practices. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 513-526.	1.9	66
232	Allogenic Fecal Microbiota Transplantation in Patients With Nonalcoholic Fatty Liver Disease Improves Abnormal Small Intestinal Permeability: A Randomized Control Trial. <i>American Journal of Gastroenterology</i> , 2020, 115, 1055-1065.	0.2	177
233	A Universal Gut-Microbiome-Derived Signature Predicts Cirrhosis. <i>Cell Metabolism</i> , 2020, 32, 878-888.e6.	7.2	167
234	Mechanisms, screening modalities and treatment options for individuals with non-alcoholic fatty liver disease and type 2 diabetes. <i>Diabetic Medicine</i> , 2020, 37, 1793-1806.	1.2	9
235	Non-invasive diagnosis: non-alcoholic fatty liver disease and alcoholic liver disease. <i>Translational Gastroenterology and Hepatology</i> , 2020, 5, 31-31.	1.5	25
237	Discordant pathological diagnosis of non-alcoholic fatty liver disease: A prospective multicenter study. <i>JGH Open</i> , 2020, 4, 497-502.	0.7	22
238	NAFLD and NASH. , 2020, , .		1
239	Management of nonalcoholic fatty liver disease and the role of bariatric surgery: a brief review for surgeons. <i>Surgery for Obesity and Related Diseases</i> , 2020, 16, 699-703.	1.0	4
240	Simultaneous multislice rapid magnetic resonance elastography of the liver. <i>NMR in Biomedicine</i> , 2020, 33, e4252.	1.6	13
241	Nonalcoholic Fatty Liver Disease 2020: The State of the Disease. <i>Gastroenterology</i> , 2020, 158, 1851-1864.	0.6	710
242	Magnetic resonance elastography quantification of the solid-to-fluid transition of liver tissue due to decellularization. <i>Journal of the Mechanical Behavior of Biomedical Materials</i> , 2020, 104, 103640.	1.5	16

#	ARTICLE	IF	CITATIONS
243	Prevalence of significant hepatic fibrosis using magnetic resonance elastography in a health checkâ€¦up clinic population. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 388-396.	1.9	22
244	Cost Effectiveness of Different Strategies for Detecting Cirrhosis in Patients With Nonalcoholic Fatty Liver Disease Based on United States Health Care System. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2305-2314.e12.	2.4	38
245	Magnetic resonance elastography in staging liver fibrosis in non-alcoholic fatty liver disease: a pooled analysis of the diagnostic accuracy. <i>BMC Gastroenterology</i> , 2020, 20, 89.	0.8	26
246	MRI quantification techniques in fatty liver: the diagnostic performance of hepatic T1, T2, and stiffness measurements in relation to the proton density fat fraction. <i>Diagnostic and Interventional Radiology</i> , 2021, 27, 7-14.	0.7	16
247	Nuclear hormone and peptide hormone therapeutics for NAFLD and NASH. <i>Molecular Metabolism</i> , 2021, 46, 101153.	3.0	10
248	A portable single-sided magnetic-resonance sensor for the grading of liver steatosis and fibrosis. <i>Nature Biomedical Engineering</i> , 2021, 5, 240-251.	11.6	21
249	Clinical Utility of Mac-2 Binding Protein Glycosylation Isomer in Chronic Liver Diseases. <i>Annals of Laboratory Medicine</i> , 2021, 41, 16-24.	1.2	27
251	Multiparametric Magnetic Resonance Imaging, Autoimmune Hepatitis, and Prediction of Disease Activity. <i>Hepatology Communications</i> , 2021, 5, 1009-1020.	2.0	20
252	Automated Analysis of Multiparametric Magnetic Resonance Imaging/Magnetic Resonance Elastography Exams for Prediction of Nonalcoholic Steatohepatitis. <i>Journal of Magnetic Resonance Imaging</i> , 2021, 54, 122-131.	1.9	16
253	Evaluation of MR elastography for prediction of lymph node metastasis in prostate cancer. <i>Abdominal Radiology</i> , 2021, 46, 3387-3400.	1.0	12
254	Prevalence of liver fibrosis and associated risk factors in the Korean general population: a retrospective cross-sectional study. <i>BMJ Open</i> , 2021, 11, e046529.	0.8	20
255	Identifying Advanced Fibrosis in NAFLD Using Noninvasive Tests. <i>Journal of Clinical Gastroenterology</i> , 2021, Publish Ahead of Print, .	1.1	2
256	Viscoelasticity of children and adolescent brains through MR elastography. <i>Journal of the Mechanical Behavior of Biomedical Materials</i> , 2021, 115, 104229.	1.5	16
257	Magnetic resonance elastography biomarkers for detection of histologic alterations in nonalcoholic fatty liver disease in the absence of fibrosis. <i>European Radiology</i> , 2021, 31, 8408-8419.	2.3	6
258	Two-dimensional shear wave elastography and ultrasound-guided attenuation parameter for progressive non-alcoholic steatohepatitis. <i>PLoS ONE</i> , 2021, 16, e0249493.	1.1	17
259	Preliminary experience with 3T magnetic resonance elastography imaging of the liver. <i>South African Journal of Radiology</i> , 2021, 25, 2072.	0.1	0
260	A porohyperviscoelastic model for the shear wave elastography of the liver. <i>Journal of the Mechanics and Physics of Solids</i> , 2021, 150, 104339.	2.3	15
261	KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease. <i>Clinical and Molecular Hepatology</i> , 2021, 27, 363-401.	4.5	152

#	ARTICLE	IF	CITATIONS
262	Imaging biomarkers of NAFLD, NASH, and fibrosis. <i>Molecular Metabolism</i> , 2021, 50, 101167.	3.0	83
263	Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort. <i>Journal of Hepatology</i> , 2021, 75, 284-291.	1.8	124
264	Nonalcoholic fatty liver disease: use of diagnostic biomarkers and modalities in clinical practice. <i>Expert Review of Molecular Diagnostics</i> , 2021, 21, 1065-1078.	1.5	6
265	Magnetic Resonance Elastography for the Clinical Risk Assessment of Fibrosis, Cirrhosis, and Portal Hypertension in Patients With NAFLD. <i>Journal of Clinical and Experimental Hepatology</i> , 2022, 12, 174-179.	0.4	2
266	Intestinal microbiota participates in nonalcoholic fatty liver disease progression by affecting intestinal homeostasis. <i>World Journal of Clinical Cases</i> , 2021, 9, 6654-6662.	0.3	2
267	What Does the Future Hold for Patients With Nonalcoholic Steatohepatitis: Diagnostic Strategies and Treatment Options in 2021 and Beyond?. <i>Hepatology Communications</i> , 2021, 5, 1810-1823.	2.0	18
268	Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 1150-1161.	1.9	79
269	Imaging Approaches to Monitor Inflammasome Activation. <i>Journal of Molecular Biology</i> , 2022, 434, 167251.	2.0	11
270	Non-invasive imaging biomarkers to assess nonalcoholic fatty liver disease: A review. <i>Clinical Imaging</i> , 2021, 78, 22-34.	0.8	9
271	Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis. <i>Journal of Hepatology</i> , 2021, 75, 770-785.	1.8	149
272	The Diagnostic Accuracy of LOGIQ S8 and E9 Shear Wave Elastography for Staging Hepatic Fibrosis, in Comparison with Transient Elastography. <i>Diagnostics</i> , 2021, 11, 1817.	1.3	3
273	Molecular MR Contrast Agents. <i>Investigative Radiology</i> , 2021, 56, 20-34.	3.5	25
274	Effects of Canagliflozin on Hepatic Steatosis, Visceral Fat and Skeletal Muscle among Patients with Type 2 Diabetes and Non-alcoholic Fatty Liver Disease. <i>Internal Medicine</i> , 2021, 60, 3391-3399.	0.3	11
275	Effect of breath holding at the end of the inspiration and expiration phases on liver stiffness measured by 2D-MR elastography. <i>Abdominal Radiology</i> , 2021, 46, 2516-2526.	1.0	4
276	Non-alcoholic Fatty Liver Disease and Diabetes Mellitus. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1307, 417-440.	0.8	21
277	Diffuse Liver Disease: Cirrhosis, Focal Lesions in Cirrhosis, and Vascular Liver Disease. <i>IDKD Springer Series</i> , 2018, , 229-236.	0.8	8
278	Proteomic screening of plasma identifies potential noninvasive biomarkers associated with significant/advanced fibrosis in patients with nonalcoholic fatty liver disease. <i>Bioscience Reports</i> , 2020, 40, .	1.1	21
279	Impact of the Analytical Approach on the Reliability of MRI-Based Assessment of Hepatic Fat Content. <i>Current Developments in Nutrition</i> , 2020, 4, nzaa171.	0.1	2

#	ARTICLE	IF	CITATIONS
280	Recent advances in non-invasive diagnosis and medical management of non-alcoholic fatty liver disease in adult. <i>Egyptian Liver Journal</i> , 2020, 10, .	0.3	32
281	Clinical Trial Design for Alpha-1 Antitrypsin Deficiency: A Model for Rare Diseases. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2014, 2, 177-190.	0.5	7
282	Bariatric Surgery for the Treatment of Nonalcoholic Fatty Liver Disease: Is Vertical Sleeve Gastrectomy the Best Future Option?. <i>Journal of Gastroenterology and Hepatology Research</i> , 2016, 5, 1957-1961.	0.2	2
283	The Relevance of Noninvasive Tools To Assess Fibrosis in Non-Alcoholic Fatty Liver Disease. <i>Current Pharmaceutical Design</i> , 2020, 26, 3928-3938.	0.9	3
284	Noninvasive imaging assessment of non-alcoholic fatty liver disease: Focus on liver scintigraphy. <i>World Journal of Gastroenterology</i> , 2015, 21, 4432-4439.	1.4	7
285	Clinical assessment and management of liver fibrosis in non-alcoholic fatty liver disease. <i>World Journal of Gastroenterology</i> , 2020, 26, 5919-5943.	1.4	33
286	Noninvasive Evaluation of Nonalcoholic Fatty Liver Disease. <i>Endocrinology and Metabolism</i> , 2020, 35, 243-259.	1.3	23
287	Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus: A Position Statement of the Fatty Liver Research Group of the Korean Diabetes Association. <i>Diabetes and Metabolism Journal</i> , 2020, 44, 382.	1.8	46
288	Nonalcoholic fatty liver disease burden “ Saudi Arabia and United Arab Emirates, 2017”2030. <i>Saudi Journal of Gastroenterology</i> , 2018, 24, 211.	0.5	77
289	Efficacy of long-term rifaximin treatment for hepatic encephalopathy in the Japanese. <i>World Journal of Hepatology</i> , 2019, 11, 531-541.	0.8	13
290	Clinical applications, limitations and future role of transient elastography in the management of liver disease. <i>World Journal of Gastrointestinal Pharmacology and Therapeutics</i> , 2016, 7, 91.	0.6	54
291	Noninvasive Assessment of Advanced Fibrosis Based on Hepatic Volume in Patients with Nonalcoholic Fatty Liver Disease. <i>Gut and Liver</i> , 2017, 11, 674-683.	1.4	12
292	Recurrent NASH Post-liver Transplant: Implications and Treatment. <i>Current Hepatology Reports</i> , 2021, 20, 108.	0.4	0
293	Hepatic Steatosis. , 2016, , 186-189.		0
295	Recurrent Primary Disease After Liver Transplantation. , 2018, , 784-815.e14.		0
296	Magnetic Resonance Elastography of the Liver. , 2018, , 225-238.		1
297	Clinical Manifestations of Liver Disease in Diabetes Mellitus. <i>Clinical Gastroenterology</i> , 2018, , 275-315.	0.0	0
298	Liver Magnetic Resonance Elastography: Clinical Use and Interpretation. , 2020, , 69-93.		2

#	ARTICLE	IF	CITATIONS
299	MR Based-Imaging Biomarkers in NAFLD/NASH. , 2020, , 141-156.		0
300	Liver stiffness measured by virtual touch quantification predicts the occurrence of posthepatectomy refractory ascites in patients with hepatocellular carcinoma. Surgery Today, 2022, 52, 822-831.	0.7	2
301	Noninvasive Diagnostic Approach to NASH: Radiological Diagnostics. , 2020, , 257-269.		0
302	Fibrosis Assessment in Patients with NAFLD. , 2020, , 123-139.		1
303	Diagnostic Algorithm for the Identification of NAFLD in Primary Care. , 2020, , 225-234.		0
304	Non-alcoholic Fatty Liver Disease: A Global Public Health Issue. , 2020, , 321-333.		2
305	Extracellular Vesicles in Non-alcoholic Fatty Liver Disease: Key Players in Disease Pathogenesis and Promising Biomarker Tools. , 2020, , 157-180.		0
306	Magnetic resonance elastography in a rabbit model of liver fibrosis: a 3-T longitudinal validation for clinical translation. American Journal of Translational Research (discontinued), 2016, 8, 4922-4931.	0.0	2
307	Noninvasive Assessment of Fibrosis Regression in Hepatitis C Virus Sustained Virologic Responders. Gastroenterology and Hepatology, 2017, 13, 587-595.	0.2	8
308	Diagnostic and Treatment Implications of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Gastroenterology and Hepatology, 2019, 15, 83-89.	0.2	9
309	ASMBS Position Statement on the Impact of Metabolic and Bariatric Surgery on Nonalcoholic Steatohepatitis. Surgery for Obesity and Related Diseases, 2022, 18, 314-325.	1.0	8
310	Quantitative evaluation of hepatic fibrosis by fibro Scan and Gd-EOB-DTPA-enhanced T1 mapping magnetic resonance imaging in chronic hepatitis B. Abdominal Radiology, 2022, 47, 684-692.	1.0	6
311	Noninvasive Risk Stratification for Nonalcoholic Fatty Liver Disease Among Living Liver Donor Candidates: A Proposed Algorithm. Liver Transplantation, 2022, 28, 670-677.	1.3	3
312	Subclinical steatohepatitis and advanced liver fibrosis in health examinees with nonalcoholic fatty liver disease (NAFLD) in 10 South Korean cities: A retrospective cross-sectional study. PLoS ONE, 2021, 16, e0260477.	1.1	2
313	Comparative diagnostic performance of ultrasound shear wave elastography and magnetic resonance elastography for classifying fibrosis stage in adults with biopsy-proven nonalcoholic fatty liver disease. European Radiology, 2022, 32, 2457-2469.	2.3	19
314	OUP accepted manuscript. Gastroenterology Report, 2022, 10, goac005.	0.6	2
315	Inhibition of 11 β -Hydroxysteroid dehydrogenase α 1 with <sc>AZD4017</sc> in patients with nonalcoholic steatohepatitis or nonalcoholic fatty liver disease: A randomized, double-blind, placebo-controlled, phase <sc>II</sc> study. Diabetes, Obesity and Metabolism, 2022, 24, 881-890.	2.2	16
316	Conventional and artificial intelligence-based imaging for biomarker discovery in chronic liver disease. Hepatology International, 2022, 16, 509-522.	1.9	16

#	ARTICLE	IF	CITATIONS
317	MR elastography in nonalcoholic fatty liver disease: inter-center and inter-analysis-method measurement reproducibility and accuracy at 3T. <i>European Radiology</i> , 2022, 32, 2937-2948.	2.3	12
318	Influence of liver stiffness heterogeneity on staging fibrosis in patients with nonalcoholic fatty liver disease. <i>Hepatology</i> , 2022, 76, 186-195.	3.6	9
319	Tagging incidental finding of fatty liver on ultrasound: A novel intervention to improve early detection of liver fibrosis. <i>Journal of Clinical and Translational Research</i> , 2021, 7, 641-647.	0.3	0
320	Updates on novel pharmacotherapeutics for the treatment of nonalcoholic steatohepatitis. <i>Acta Pharmacologica Sinica</i> , 2022, 43, 1180-1190.	2.8	22
321	Evaluation of Magnetic Resonance Elastography and Transient Elastography for Liver Fibrosis and Steatosis Assessments in the Liver Transplant Setting. , 2022, 33, 153-160.		3
322	Comparison of clinical prediction rules for ruling out cirrhosis in nonalcoholic fatty liver disease (<scp>NAFLD</scp>). <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 1441-1451.	1.9	9
323	Quantitative magnetic resonance imaging to aid clinical decision making in autoimmune hepatitis. <i>EClinicalMedicine</i> , 2022, 46, 101325.	3.2	8
324	Dynamic X-ray elastography using a pulsed photocathode source. <i>Scientific Reports</i> , 2021, 11, 24128.	1.6	1
325	Evaluation of a single-breath-hold radial turbo-spin-echo sequence for T2 mapping of the liver at 3T. <i>European Radiology</i> , 2022, 32, 3388-3397.	2.3	5
326	The Combination of <scp>MR</scp> Elastography and Proton Density Fat Fraction Improves Diagnosis of Nonalcoholic Steatohepatitis. <i>Journal of Magnetic Resonance Imaging</i> , 2022, 56, 368-379.	1.9	5
327	Prognostic utility of magnetic resonance elastography and MEFIB index in predicting liver-related outcomes and mortality in individuals at risk of and with nonalcoholic fatty liver disease. <i>Therapeutic Advances in Gastroenterology</i> , 2022, 15, 175628482210938.	1.4	18
328	Plasma Aldo-Keto Reductase Family 1 Member B10 as a Biomarker Performs Well in the Diagnosis of Nonalcoholic Steatohepatitis and Fibrosis. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5035.	1.8	2
329	Lipotoxicity as the Leading Cause of Non-Alcoholic Steatohepatitis. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5146.	1.8	22
330	Diagnostic Feasibility of Magnetic Resonance Elastography Radiomics Analysis for the Assessment of Hepatic Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. <i>Journal of Computer Assisted Tomography</i> , 2022, Publish Ahead of Print, .	0.5	3
331	Impact of non-invasive biomarkers on hepatology practice: Past, present and future. <i>Journal of Hepatology</i> , 2022, 76, 1362-1378.	1.8	78
332	Non-invasive diagnosis and staging of non-alcoholic fatty liver disease. <i>Hormones</i> , 2022, 21, 349-368.	0.9	12
333	MRI in liver cirrhosis. , 2022, 1, 23-41.		0
334	Current therapies and new developments in NASH. <i>Gut</i> , 2022, 71, 2123-2134.	6.1	82

#	ARTICLE	IF	CITATIONS
335	Non-Alcoholic Fatty Liver Disease and Extrahepatic Cancers: A Wolf in Sheep's Clothing?. <i>Current Oncology</i> , 2022, 29, 4478-4510.	0.9	6
336	Liver stiffness accuracy by MR elastography in histologically proven non-alcoholic fatty liver disease patients: a Spanish cohort. <i>Revista Espanola De Enfermedades Digestivas</i> , 2022, , .	0.1	1
337	Elevated de novo lipogenesis, slow liver triglyceride turnover, and clinical correlations in nonalcoholic steatohepatitis patients. <i>Journal of Lipid Research</i> , 2022, 63, 100250.	2.0	7
338	Magnetic resonance imaging for the assessment of pathological hepatic findings in nonalcoholic fatty liver disease. <i>Choonpa Igaku</i> , 2022, , .	0.0	0
339	Clinical studies of magnetic resonance elastography from 1995 to 2021: Scientometric and visualization analysis based on CiteSpace. <i>Quantitative Imaging in Medicine and Surgery</i> , 2022, 12, 5080-5100.	1.1	4
340	Magnetic resonance elastography of malignant tumors. <i>Frontiers in Physics</i> , 0, 10, .	1.0	3
341	A comparison of magnetic resonance elastography (MRE) to biomarker testing for staging fibrosis in non-alcoholic fatty liver disease (NAFLD). <i>Translational Gastroenterology and Hepatology</i> , 0, 8, 7-7.	1.5	1
342	Radiofrequency coil design for improving human liver fat quantification in a portable single-side magnetic resonance system. <i>NMR in Biomedicine</i> , 2023, 36, .	1.6	2
343	A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes. <i>Journal of Hepatology</i> , 2023, 78, 471-478.	1.8	55
344	Practical Diagnosis and Staging of Nonalcoholic Fatty Liver Disease: A Narrative Review. <i>European Medical Journal (Chelmsford, England)</i> , 0, , 108-118.	3.0	9
345	Noninvasive imaging biomarkers for liver fibrosis in nonalcoholic fatty liver disease: current and future. <i>Clinical and Molecular Hepatology</i> , 2023, 29, S136-S149.	4.5	10
346	SWOT analysis of noninvasive tests for diagnosing NAFLD with severe fibrosis: an expert review by the JANIT Forum. <i>Journal of Gastroenterology</i> , 2023, 58, 79-97.	2.3	6
347	Chronic kidney disease in nonalcoholic fatty liver disease at primary healthcare centers in Korea. <i>PLoS ONE</i> , 2022, 17, e0279367.	1.1	2
348	Non-invasive methods to evaluate liver fibrosis in patients with non-alcoholic fatty liver disease. <i>Frontiers in Physiology</i> , 0, 13, .	1.3	5
349	Circulating miRNAs associated with nonalcoholic fatty liver disease. <i>American Journal of Physiology - Cell Physiology</i> , 2023, 324, C588-C602.	2.1	14
350	Non-alcoholic Steatohepatitis: Global Impact and Clinical Consequences. <i>European Medical Journal Hepatology</i> , 0, , 74-83.	1.0	0
351	Updates on Quantitative MRI of Diffuse Liver Disease: A Narrative Review. <i>BioMed Research International</i> , 2022, 2022, 1-15.	0.9	2
352	AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. <i>Hepatology</i> , 2023, 77, 1797-1835.	3.6	358

#	ARTICLE	IF	CITATIONS
353	The Link between NAFLD and Metabolic Syndrome. <i>Diagnostics</i> , 2023, 13, 614.	1.3	10
354	Conventional liver imaging in hepatitis. , 2023, , 61-86.		0
355	Comparison of liver fibrosis scores for predicting mortality and morbidity in heart failure with preserved ejection fraction. <i>ESC Heart Failure</i> , 2023, 10, 1771-1780.	1.4	5
356	Roles of Radiological Tests in Clinical Trials and the Clinical Management of Nonalcoholic Fatty Liver Disease. <i>Clinics in Liver Disease</i> , 2023, 27, 363-372.	1.0	2
357	Prospective study of a case-finding algorithm to detect NAFLD with advanced fibrosis in primary care patients. <i>Hepatology Communications</i> , 2023, 7, e0024-e0024.	2.0	1
358	Prevalence of non-alcoholic fatty liver disease in a multicentre cohort of people living with HIV in Spain.. <i>European Journal of Internal Medicine</i> , 2023, 110, 54-61.	1.0	4
359	Noninvasive assessment of liver disease severity: image-related. , 2023, , 3-29.		0
360	Defining the optimal technique for endoscopic ultrasound shear wave elastography: a combined benchtop and animal model study with comparison to transabdominal shear wave elastography. <i>Clinical Endoscopy</i> , 2023, 56, 229-238.	0.6	1
361	Challenges and opportunities in NASH drug development. <i>Nature Medicine</i> , 2023, 29, 562-573.	15.2	51
362	Noninvasive assessment of liver steatosis with ultrasound techniques. , 2024, , 177-198.		0
363	Non-invasive diagnosis and monitoring of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. <i>The Lancet Gastroenterology and Hepatology</i> , 2023, 8, 660-670.	3.7	18
364	CT Texture Analysis in Nonalcoholic Fatty Liver Disease (NAFLD). <i>Journal of Clinical and Experimental Hepatology</i> , 2023, 13, 760-766.	0.4	1
365	Non-alcoholic Fatty Liver Disease Associated Hepatocellular Carcinoma. , 0, , .		0